Treatment With Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma.
Ontology highlight
ABSTRACT: To date, cancer genomic medicine, using cancer gene panel covered by health insurance from June 2019, has been performed for advanced malignant tumors under public medical insurance. In gynecology, the first-line treatment for uterine leiomyosarcomas, which is a mesenchymal uterine tumor, is surgery. In uterine leiomyosarcoma cases, recurrence is observed within 2 years postoperatively; however, to date, clinical trials have not shown efficacy with existing antitumor agents. We noted efficacy in two cases with advanced/recurrent uterine leiomyosarcoma using an antitumor agent selected on the basis of cancer gene panel testing results. Following uterine leiomyosarcoma diagnosis, they underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy as standard surgical treatment. A
SUBMITTER: Hayashi T
PROVIDER: S-EPMC10769602 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA